Method for determining quetiapine drug concentration reference range based on regional difference

Abstract

The invention discloses a method for determining a quetiapine drug concentration reference range based on regional difference. The method comprises the following steps: dividing a geographic region; for each divided area, obtaining a psychosis rating scale evaluation result and electroencephalogram information of the patient without using quetiapine, obtaining a psychosis rating scale evaluation result, electroencephalogram information, plasma concentration information and adverse reaction information of the patient after using the quetiapine according to different doses, and determining a plasma concentration range suitable for each patient; according to the blood concentration range suitable for each patient in the region, the total region blood concentration range is obtained; taking an interval with confidence greater than a preset threshold value in the total regional blood concentration range as a quetiapine drug concentration reference range in the region. According to the method, region division is carried out, the reference range of the quetiapine drug concentration suitable for people in each region is determined based on the division result, the reference range with higher reference value is provided, and the probability that the drug effect reaches the standard is greatly improved.

Description

Technical Field

[0001] The present invention relates to the technical field of drug use, and in particular to a method for determining a reference range of quetiapine drug concentration based on regional differences. Background Art

[0002] Mental illness refers to clinical manifestations characterized by varying degrees of impairment in cognitive, emotional, volitional, and behavioral mental activities, resulting from brain dysfunction under the influence of various biological, psychological, and social factors. Most patients with mental illness experience a prolonged course of illness, fluctuating symptoms, and are prone to relapse, requiring consistent and regular medication to control symptoms and prevent relapse.

[0003] Quetiapine, as a commonly used drug for mental illness, is commonly used for various types of schizophrenia. It is not only effective for the positive symptoms of schizophrenia, but also has a certain effect on the negative symptoms. It can also alleviate the emotional symptoms related to schizophrenia such as depression, anxiety and cognitive deficits.

[0004] Due to differences in dietary habits, living environments, etc. among people in different geographical regions, their drug metabolism abilities may be different. The same drug dose may have different efficacy (drug concentration) for patients in different regions. The same is true for quetiapine. The same drug dose of quetiapine often has certain differences in efficacy for patients with mental illness in different geographical regions. Therefore, in order to ensure that the drug effect meets the standard, to reduce the harm of excessive drug concentration to the patient's body (including drug poisoning), and to reduce the recurrence of the disease or unsatisfactory disease control effect caused by insufficient drug concentration, it is urgent to develop a method for determining the reference range of quetiapine drug concentration based on regional differences, so as to determine a quetiapine drug concentration reference range that is more suitable for the geographical region. Summary of the Invention

[0005] In view of the above problems, the present invention provides a method for determining a reference range of quetiapine drug concentration based on regional differences.

[0006] The technical solutions adopted by the present invention to solve the technical problems are as follows:

[0007] In a first aspect, the present invention provides a method for determining a reference range of quetiapine drug concentration based on regional differences, comprising:

[0008] S1. Divide geographical areas;

[0009] S2. For each divided area, perform the following steps:

[0010] S21. Obtain the patient's psychiatric rating scale results and electroencephalogram information before taking quetiapine;

[0011] S22. Obtain the patient's psychiatric rating scale assessment results, electroencephalogram (EEG) information, blood drug concentration information, and adverse reaction information after taking different drug doses;

[0012] S23. Determine the appropriate blood drug concentration range for each patient;

[0013] S24. Obtaining a regional total blood drug concentration range based on the blood drug concentration range applicable to each patient in the region;

[0014] S25. The confidence interval in the total range of regional blood drug concentration that is greater than the preset threshold is taken as the reference range of quetiapine drug concentration in the region.

[0015] In a preferred embodiment, the S21 also includes: obtaining the patient's basic information, which includes liver and kidney function information, thyroid function information, basal metabolic information, and body temperature information; the S24 specifically includes: eliminating the data of patients with abnormal basic information, and obtaining the total regional blood drug concentration range based on the blood drug concentration range applicable to each patient with normal basic information in the region.

[0016] In a preferred embodiment, the determination method further comprises step S3, analyzing the impact of regional characteristics on the reference range of quetiapine drug concentration in the region based on the regional characteristics of the region, the reference range of quetiapine recommended by the guidelines, and the reference range of quetiapine drug concentration in the region of each region.

[0017] In a preferred embodiment, the step S2 further includes calculating the median, mean and standard deviation of the total blood drug concentration range of the region or the reference range of quetiapine drug concentration in the region.

[0018] In a preferred embodiment, the influence of the characteristics of the analysis area on the reference range of quetiapine drug concentration in the area is further based on the median, mean and standard deviation of the total range of regional blood drug concentration or the blood drug concentration of the reference range of quetiapine drug concentration in the area.

[0019] In a preferred embodiment, the S23 specifically includes: detecting the blood drug concentration of each patient; if the patient has an adverse reaction, determining that the blood drug concentration is a blood drug concentration that is not suitable for the patient; when the patient does not have an adverse reaction, comparing the patient's psychiatric rating scale evaluation results before using quetiapine with the patient's psychiatric rating scale evaluation results after taking the drug to obtain a first comparison result, and comparing the patient's electroencephalogram information before using quetiapine with the patient's electroencephalogram information after taking the drug to obtain a second comparison result, if the first comparison result exceeds the first requirement and / or the second comparison result exceeds the second requirement, then determining that the blood drug concentration is a blood drug concentration that is suitable for the patient; otherwise, determining that the blood drug concentration is a blood drug concentration that is not suitable for the patient.

[0020] In a preferred embodiment, the S1 is specifically to obtain several regions by geographical division based on natural and cultural characteristics.

[0021] In a second aspect, the present invention provides a system for determining a reference range of quetiapine drug concentration based on regional differences, comprising:

[0022] A division module, used to divide geographical areas;

[0023] An acquisition module is used to obtain the psychiatric rating scale evaluation results and electroencephalogram information of patients before taking quetiapine, and to obtain the psychiatric rating scale evaluation results, electroencephalogram information, blood drug concentration information, and adverse reaction information of patients after taking different doses of the drug;

[0024] The range determination module is used to determine the blood drug concentration range applicable to each patient, to obtain the regional blood drug concentration total range based on the blood drug concentration range applicable to each patient in the region, and to take the interval with a confidence level greater than a preset threshold in the regional blood drug concentration total range as the reference range of quetiapine drug concentration in the region.

[0025] In a third aspect, the present invention provides an electronic device comprising: a memory; one or more processors; one or more programs, wherein the one or more programs are stored in the memory and configured to be executed by the one or more processors, and the one or more programs include instructions for executing any one of the methods for determining a reference range of quetiapine drug concentration based on regional differences according to the first aspect.

[0026] In a fourth aspect, the present invention provides a storage medium storing a computer program. When the computer program is executed by a processor, the steps of the method for determining a reference range of quetiapine drug concentration based on regional differences described in the first aspect are implemented.

[0027] The present invention discloses a method for determining a reference range of quetiapine drug concentration based on regional differences. The method divides regions into geographical areas, and determines the reference range of quetiapine drug concentration for each region based on the three dimensions of psychiatric rating scale evaluation results, electroencephalogram information, and adverse reaction information. The method includes performing a confidence screening to ensure the accuracy and universality of the range determination within the region. With this design, the present invention provides a reference range with greater reference value. Based on the results of this method, the harm to the human body caused by excessive drug concentration can be reduced. At the same time, the occurrence of disease recurrence or unsatisfactory disease control effects caused by insufficient drug concentration can be reduced, thereby significantly improving the probability of achieving the drug effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for use in the embodiments. It should be understood that the following drawings only illustrate certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other relevant drawings can be obtained based on these drawings without paying any creative work.

[0029] Figure 1 The figure is a flow chart of a method for determining a reference range of quetiapine drug concentration based on regional differences;

[0030] Figure 2 A framework diagram of a system for determining a reference range of quetiapine drug concentration based on regional differences;

[0031] Figure 3 This is an example diagram of an electronic device. DETAILED DESCRIPTION

[0032] In order to more clearly understand the above-mentioned objects, features and advantages of the present invention, the present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.

[0033] In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention may also be implemented in other ways different from those described herein. Therefore, the scope of protection of the present invention is not limited to the specific embodiments disclosed below.

[0034] In order to ensure that the drug effect of quetiapine in different regions meets the standard, this application provides a method for determining the reference range of quetiapine drug concentration based on regional differences, see Figure 1 , the method comprising:

[0035] S1. Divide geographical areas;

[0036] S2. For each divided area, perform steps S21 to S25 respectively.

[0037] S21. Obtain the patient's psychiatric rating scale results and electroencephalogram information before taking quetiapine;

[0038] S22. Obtain the patient's psychiatric rating scale assessment results, electroencephalogram (EEG) information, blood drug concentration information, and adverse reaction information after taking different drug doses;

[0039] S23. Determine the appropriate blood drug concentration range for each patient;

[0040] S24. Obtaining a regional total blood drug concentration range based on the blood drug concentration range applicable to each patient in the region;

[0041] S25. The confidence interval in the total range of regional blood drug concentration that is greater than the preset threshold is taken as the reference range of quetiapine drug concentration in the region.

[0042] In this embodiment, geographical division is performed based on natural and cultural characteristics, such as geographical location, natural environment, cultural characteristics, and eating habits.

[0043] For each geographical area, the psychiatric rating scale evaluation results and electroencephalogram (EEG) information of several patients who did not use quetiapine were obtained. For patients who did not use quetiapine, the psychiatric rating scale test was performed to obtain the evaluation results, and the EEG test was performed to obtain the EEG information, which was called the EEG information before drug use.

[0044] Given existing drug instructions, the dosage can be adjusted appropriately based on patient response, for example, exceeding or falling below the instructions. Here, quetiapine is administered at a daily dose of 300-450 mg. This dosage can be adjusted to 150-750 mg daily based on the patient's clinical response and tolerance. The 300-450 mg dosage can be divided into four different doses: 300 mg, 350 mg, 400 mg, and 450 mg. Patients are not required to take each dose according to the different dosages; this can be determined based on specific circumstances. For example, if a patient responds to 150 mg, they may be tested with 450 mg.

[0045] For the above patients, the psychiatric rating scale evaluation results, electroencephalogram information, blood drug concentration information, and adverse reaction information were obtained after the patients took the drugs at different doses.

[0046] The blood collection time corresponding to blood drug concentration information can refer to existing relevant guidelines. For example, quetiapine is a drug with an elimination half-life of less than 12 hours. For psychotropic drugs with an elimination half-life of 4-12 hours, the TDM blood collection time and the last medication dose time should be relatively fixed to obtain more stable TDM results. In other words, the medication and blood collection times should be relatively fixed to reduce diurnal fluctuations in TDM results.

[0047] In this embodiment, the patient's blood is processed as follows:

[0048] Collect 3-5 ml of whole blood using a red-capped glass tube without any additives and centrifuge at 3500 rpm for 10 minutes. Liquid chromatograph mobile phase A: Add 1 ml each of Zhejiang Disai Mobile Phase Additives A1 and A2 to 1000 ml of deionized water and mix ultrasonically. Mobile phase B: Add 1 ml of Zhejiang Disai Mobile Phase Additive B1 to 1000 ml of methanol and mix ultrasonically. Instrument-related procedures: ① Tune and calibrate the mass spectrometer Q1 and Q3 for positive ions; ② Optimize compound parameters; ③ Establish an LC-MS method; ④ Create a sampling list. Place 50 μl of sample serum (standard, quality control) into a centrifuge tube, add 150 μl of precipitant and internal standard solution, vortex mix for 5 minutes, centrifuge at 15,000 rpm for 10 minutes, and add 10 μl of the supernatant to 100 μl of diluent. Mix thoroughly, then place in a sample plate for analysis. A KLP-SPZ-004 (4.0 μm, 50 mm*2.0 mm) chromatographic column was used, and gradient elution was adopted: 0-0.3 min 20% B, 0.3-1.0 min 70% B, 1.0-2.6 min 90% B,

[0049] 20% B for 2.6-3.0 min, flow rate 0.6 ml / min. Mass spectrometry detection was performed using an electrospray ionization source in positive ion monitoring mode. The mass spectrometry parameters for quetiapine were: Q1Mass: 384.20 Da, Q3Mass: 221.20 Da, Dwell Time: 10.00 msec, Declustering Potential DP: 90.00 V, Collision Voltage CE: 50.00 eV, and Exit Voltage CXP: 18.00 V. The processing included generating a quetiapine concentration standard curve.

[0050] For EEG information, the time corresponding to the collection of the patient's EEG information can be almost equal to the time corresponding to the blood drug concentration information, or the EEG information can be sleep EEG information. Changes in brain waves are one of the biological bases of depression.

[0051] The blood drug concentration range applicable to each patient requires a lower limit and an upper limit. The upper limit can be the lowest concentration at which adverse reactions occur, or the upper threshold concentration, which is mainly obtained by calculating the expected dose-related blood drug concentration at the maximum dose in the instructions. The minimum dose at which the condition improves is the lower limit. As an example, based on the severity determined by the BPRS scale, the minimum dose is used according to the drug instructions, and the patient is evaluated using the PANSS scale every two weeks. If the condition improves, the drug concentration is tested and recorded as a statistical low value data.

[0052] Here, the S23 is specifically:

[0053] The blood drug concentration of each patient is detected. Specifically, when the first comparison result exceeds the first requirement or the second comparison result exceeds the second requirement, the blood drug concentration of each patient is detected. For each patient, if the patient has an adverse reaction (adverse reaction information is none), the corresponding blood drug concentration is determined to be a blood drug concentration that is not suitable for the patient; when the patient does not have an adverse reaction, the first comparison result is obtained by comparing the patient's psychiatric rating scale evaluation result before quetiapine and the patient's psychiatric rating scale evaluation result after medication, and the second comparison result is obtained by comparing the patient's electroencephalogram information before quetiapine and the patient's electroencephalogram information after medication. If the first comparison result exceeds the first requirement and / or the second comparison result exceeds the second requirement, the blood drug concentration is determined to be a blood drug concentration suitable for the patient, otherwise, the blood drug concentration is determined to be a blood drug concentration that is not suitable for the patient. The setting of the first requirement and the second requirement is not limited. For example, it can be better than the psychiatric rating scale evaluation result / electroencephalogram information without quetiapine, or the degree of improvement can be required, for example, the difference in the evaluation results needs to exceed a certain value.

[0054] It is understandable that in patients with depression, alpha waves, beta waves, theta waves, asymmetry of the left and right hemispheres, abnormalities in certain neural network connections, etc. are often reflected in the EEG information, but not all people will have changes in EEG before and after the action of quetiapine, and not all people will see rapid improvement in assessment before and after the action of quetiapine. For example, in the early stages, there may be improvement in sleep. Therefore, as long as only one of the assessment results and EEG information is effective, accuracy can be guaranteed.

[0055] In this embodiment, S21 further includes obtaining basic patient information, including liver and kidney function information, thyroid function information, basal metabolic information, and body temperature information. Accordingly, S24 specifically includes eliminating data from patients with abnormal basic information and obtaining a regional total blood drug concentration range based on the blood drug concentration range applicable to each patient in the region with normal basic information. This design improves the accuracy of determining the reference range.

[0056] If any of the liver and kidney function information, thyroid function information, basal metabolic information, and body temperature information is abnormal, the basal information is considered abnormal. If any liver and kidney function indicator is not within the normal range, the liver and kidney function is considered abnormal. If any thyroid function indicator is not within the normal range, the thyroid function is considered abnormal. If the basal metabolic information is not within the metabolic range for the patient's age, the basal metabolic rate is considered abnormal. If the body temperature is not within the normal range, it is usually a fever, which is likely to affect drug metabolism and is considered abnormal.

[0057] In the present embodiment, the determination method further comprises step S3, obtaining the regional characteristics of each region, obtaining the quetiapine reference range recommended by the guideline, and analyzing the influence of the regional characteristics on the quetiapine drug concentration reference range in the region based on the regional characteristics of the region, the quetiapine reference range recommended by the guideline, and the quetiapine drug concentration reference range in the region of each region. Regional characteristics, for example, include dietary characteristics, climatic characteristics, and environmental characteristics, for example, including that people in the region are susceptible to diseases, etc. It is not limited to which guideline, nor is it limited to only one guideline. The analysis result can usually be that a certain factor has a positive impact, no impact, or a negative impact. Specifically, the output can also include the degree of impact. Based on the analysis result, its result can be used as a reference to adjust the diet and be used as a reference when the regional reference range for other related drugs is determined.

[0058] The S3 can be implemented by an analytical model, for example, by defining that each factor has a linear relationship (or other relationship) with the blood drug concentration, integrating all information, comprehensively fitting all factors according to the reference range of quetiapine drug concentration in the region, and calculating the linear coefficient of each factor.

[0059] Said S2 also includes calculating the median, mean and standard deviation of the blood drug concentration of the total range of regional blood drug concentration or the reference range of quetiapine drug concentration in the region; said analysis of the impact of regional characteristics on the reference range of quetiapine drug concentration in the region is also based on the median, mean and standard deviation of the blood drug concentration of the total range of regional blood drug concentration or the reference range of quetiapine drug concentration in the region.

[0060] In a preferred embodiment, in S3, the blood concentration information and medication dosage of each non-excluded patient are also obtained, and the impact is analyzed accordingly.

[0061] See also Figure 2 This embodiment also provides a system for determining a reference range of quetiapine drug concentration based on regional differences, including a division module, an acquisition module, and a range determination module.

[0062] The division module is used to divide geographical areas.

[0063] The acquisition module is used to obtain the patient's psychiatric rating scale evaluation results and electroencephalogram information before taking quetiapine, and is used to obtain the patient's psychiatric rating scale evaluation results, electroencephalogram information, blood drug concentration information, and adverse reaction information after taking different doses of the drug.

[0064] The range determination module is used to determine the blood drug concentration range applicable to each patient, to obtain the total regional blood drug concentration range based on the blood drug concentration range applicable to each patient in the region, and to take the interval in the total regional blood drug concentration range with a confidence level greater than a preset threshold as the reference range of quetiapine drug concentration in the region.

[0065] In this embodiment, the acquisition module is also used to obtain basic information of the patient, which includes liver and kidney function information, thyroid function information, basal metabolic information, and body temperature information.

[0066] The range determination module is used to determine the applicable blood drug concentration range for each patient, and to obtain the regional total blood drug concentration range based on the applicable blood drug concentration range for each patient in the region. Specifically, it is used to eliminate the data of patients with abnormal basic information, and to obtain the regional total blood drug concentration range based on the applicable blood drug concentration range for each patient with normal basic information in the region.

[0067] The determination system further includes an analysis module for analyzing the impact of regional characteristics on the reference range of quetiapine drug concentration in the region based on the regional characteristics of the region, the reference range of quetiapine recommended by the guidelines, and the reference range of quetiapine drug concentration in the region of each region.

[0068] Here, the determination system further includes a calculation module for calculating the median, mean, and standard deviation of the blood drug concentration of the regional total blood drug concentration range or the regional reference range of quetiapine drug concentration. The analysis module analyzes the impact of regional characteristics on the regional reference range of quetiapine drug concentration based on the median, mean, and standard deviation of the blood drug concentration of the regional total blood drug concentration range or the regional reference range of quetiapine drug concentration, and also based on regional characteristics of the region, the quetiapine reference range recommended by the guidelines, and the regional reference range of quetiapine drug concentration in each region.

[0069] Here, the division module is specifically used to divide geographical regions into several regions according to natural and human characteristics.

[0070] Here, the range determination module is used to determine the blood drug concentration range applicable to each patient, specifically for: detecting the blood drug concentration of each patient; determining the blood drug concentration that is not applicable to the patient when the patient has adverse reactions; comparing the psychiatric rating scale evaluation results of the patient before using quetiapine and the psychiatric rating scale evaluation results of the patient after taking the drug to obtain a first comparison result, and comparing the electroencephalogram information of the patient before using quetiapine and the electroencephalogram information of the patient after taking the drug to obtain a second comparison result, when the patient does not have adverse reactions, and determining the blood drug concentration that is applicable to the patient when the first comparison result exceeds the first requirement and / or the second comparison result exceeds the second requirement; and determining the blood drug concentration that is not applicable to the patient when the first comparison result does not exceed the first requirement and the second comparison result does not exceed the second requirement.

[0071] When the system for determining the reference range of quetiapine drug concentration based on regional differences is specifically implemented, range determination can be achieved by referring to the method for determining the reference range of quetiapine drug concentration based on regional differences in any of the above embodiments, and the specific implementation steps are not repeated here.

[0072] According to the method of the present invention, an electronic device can be implemented. Figure 3 The electronic device includes: a memory; one or more processors; one or more programs, wherein the one or more programs are stored in the memory and are configured to be executed by the one or more processors, and the one or more programs include instructions for executing any one of the methods for determining the reference range of quetiapine drug concentration based on regional differences.

[0073] The processor may be a central processing unit (CPU), or other general-purpose processors, a digital signal processor (DSP), an application-specific integrated circuit (ASIC), a field-programmable gate array (FPGA) or other programmable logic devices, discrete gate or transistor logic devices, discrete hardware components, etc. The general-purpose processor may be a microprocessor or any conventional processor, etc.

[0074] The memory may include various types of storage units, such as system memory, read-only memory (ROM), and permanent storage devices. In addition, the memory may include any combination of computer-readable storage media, such as semiconductor memory chips, magnetic disks, and optical disks.

[0075] The memory stores executable codes, which, when processed by the processor, can enable the processor to execute part or all of the above-mentioned methods.

[0076] The present invention also provides a storage medium storing a computer program. When the computer program is executed by a processor, the steps of the method for determining a reference range of quetiapine drug concentration based on regional differences are implemented.

[0077] The method, system, device and storage medium for determining a reference range of quetiapine drug concentration based on regional differences of the present invention have the following effects: geographical regions are divided, and based on the divided regions, a reference range of quetiapine drug concentration is determined for each region from three dimensions: psychiatric rating scale evaluation results, electroencephalogram information and adverse reaction information, including performing confidence screening to ensure the accuracy and universality of the range determination within the region. With such a design, the present invention provides a reference range with greater reference value. Based on the results of this method, the harm to the human body caused by excessive drug concentration can be reduced, and at the same time, the occurrence of disease recurrence or unsatisfactory disease control effects caused by insufficient drug concentration can be reduced, thereby greatly improving the probability of achieving the drug effect standard.

[0078] It should be noted that, in the above embodiments, the description of each embodiment has its own focus. For parts that are not described in detail in a certain embodiment, reference can be made to the relevant description of other embodiments.

[0079] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Under the concept of the present invention, the technical features in the above embodiments or different embodiments can also be combined, the steps can be implemented in any order, and there are many other variations in different aspects of the present invention as described above. For the sake of simplicity, they are not provided in detail. Although the present invention has been described in detail with reference to the above embodiments, ordinary technicians in this field should understand that they can still modify the technical solutions described in the above embodiments, or make equivalent replacements for some of the technical features therein. These modifications or replacements do not deviate the essence of the corresponding technical solutions from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for determining a reference range of quetiapine drug concentration based on regional differences, characterized in that: include: S1. Divide geographical areas; S2. For each divided area, perform the following steps: S21. Obtain the patient's psychiatric rating scale results and electroencephalogram information before taking quetiapine; S22. Obtain the patient's psychiatric rating scale assessment results, electroencephalogram (EEG) information, blood drug concentration information, and adverse reaction information after taking different drug doses; S23. Determine the appropriate blood drug concentration range for each patient; S24. Obtaining a regional total blood drug concentration range based on the blood drug concentration range applicable to each patient in the region; S25. The confidence interval in the total range of regional blood drug concentration that is greater than the preset threshold is taken as the reference range of quetiapine drug concentration in the region.

2. The method for determining a reference range of quetiapine drug concentration based on regional differences according to claim 1, wherein: The S21 also includes: obtaining the patient's basic information, which includes liver and kidney function information, thyroid function information, basal metabolic information, and body temperature information; the S24 specifically includes: eliminating the data of patients with abnormal basic information, and obtaining the total regional blood drug concentration range based on the blood drug concentration range applicable to each patient with normal basic information in the region.

3. The method for determining a reference range of quetiapine drug concentration based on regional differences according to claim 1, wherein: The determination method further includes step S3, analyzing the influence of regional characteristics on the reference range of quetiapine drug concentration in the region based on regional characteristics of the region, the reference range of quetiapine recommended by the guidelines, and the reference range of quetiapine drug concentration in the region of each region.

4. The method for determining a reference range of quetiapine drug concentration based on regional differences according to claim 3, wherein: The S2 also includes calculating the median, mean and standard deviation of the blood drug concentration of the total range of regional blood drug concentration or the reference range of quetiapine drug concentration in the region.

5. The method for determining a reference range of quetiapine drug concentration based on regional differences according to claim 4, wherein: The analysis was also based on the median, mean, and standard deviation of the blood concentrations for the regional total blood concentration range or the reference range of quetiapine drug concentrations within the region.

6. The method for determining a reference range of quetiapine drug concentration based on regional differences according to claim 1, wherein: The S23 specifically includes: detecting the blood drug concentration of each patient; if the patient has an adverse reaction, determining that the blood drug concentration is a blood drug concentration that is not suitable for the patient; when the patient does not have an adverse reaction, comparing the patient's psychiatric rating scale evaluation results before using quetiapine with the patient's psychiatric rating scale evaluation results after using the drug to obtain a first comparison result, and comparing the patient's electroencephalogram information before using quetiapine with the patient's electroencephalogram information after using the drug to obtain a second comparison result; if the first comparison result exceeds the first requirement and / or the second comparison result exceeds the second requirement, determining that the blood drug concentration is a blood drug concentration that is suitable for the patient; otherwise, determining that the blood drug concentration is a blood drug concentration that is not suitable for the patient.

7. The method for determining a reference range of quetiapine drug concentration based on regional differences according to claim 1, wherein: The S1 is specifically to obtain several regions by geographically dividing them according to natural and humanistic characteristics.

8. A system for determining a reference range of quetiapine drug concentration based on regional differences, characterized in that: include: A division module, used to divide geographical areas; An acquisition module is used to obtain the psychiatric rating scale evaluation results and electroencephalogram information of patients before taking quetiapine, and to obtain the psychiatric rating scale evaluation results, electroencephalogram information, blood drug concentration information, and adverse reaction information of patients after taking different doses of the drug; The range determination module is used to determine the blood drug concentration range applicable to each patient, to obtain the regional blood drug concentration total range based on the blood drug concentration range applicable to each patient in the region, and to take the interval with a confidence level greater than a preset threshold in the regional blood drug concentration total range as the reference range of quetiapine drug concentration in the region.

9. An electronic device, characterized in that: include: Memory; one or more processors; One or more programs, wherein the one or more programs are stored in the memory and configured to be executed by the one or more processors, and the one or more programs include instructions for executing any one of the methods for determining a reference range of quetiapine drug concentration based on regional differences according to claims 1-7.

10. A storage medium storing a computer program, characterized in that: When the computer program is executed by a processor, the steps of the method for determining a reference range of quetiapine drug concentration based on regional differences according to any one of claims 1 to 7 are implemented.

Images